Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $224.40 | Total: $1,122.00 |
| 1 | 10 | $190.08 | Total: $1,900.80 |
| 1 | 25 | $161.04 | Total: $4,026.00 |
| 1 | 50 | $137.28 | Total: $6,864.00 |
| 1 | 100 | $118.80 | Total: $11,880.01 |
Overview
Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.Navamepent inhibits the release of several key pro-inflammatory mediators from corneal epithelial cells.Navamepent is very effective against dry eye and cupping cell loss Navamepent is effective against dry eye and cupping cell loss, and accelerates tear production.
Chemical Properties
| Molecular Formula | C18H24O4 |
| Molecular Weight | 304.38 |
| CAS Numbers | 1251537-11-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(C[C@@H](C#CC=CC=C[C@@H](CC#C)O)O)CC(OC(C)C)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Cholkar K, et al. Topical delivery of aqueous micellar resolvin E1 analog [RX-10045] [published correction appears in Int J Pharm. 2016 Jul 25;509[1-2] 528]. Int J Pharm. 2016;498[1-2] 326-334.